IDEAYA Biosciences, Inc. $IDYA Shares Acquired by Odyssean LLC

Odyssean LLC raised its holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 571.6% in the second quarter, HoldingsChannel.com reports. The firm owned 102,582 shares of the company’s stock after purchasing an additional 87,308 shares during the quarter. IDEAYA Biosciences comprises approximately 0.6% of Odyssean LLC’s holdings, making the stock its 3rd biggest holding. Odyssean LLC’s holdings in IDEAYA Biosciences were worth $3,823,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. Royal Bank of Canada increased its holdings in shares of IDEAYA Biosciences by 30.1% during the first quarter. Royal Bank of Canada now owns 122,460 shares of the company’s stock worth $2,006,000 after purchasing an additional 28,322 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of IDEAYA Biosciences by 8.2% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 57,044 shares of the company’s stock valued at $938,000 after buying an additional 4,308 shares in the last quarter. Millennium Management LLC boosted its stake in shares of IDEAYA Biosciences by 345.2% in the first quarter. Millennium Management LLC now owns 547,637 shares of the company’s stock valued at $8,970,000 after buying an additional 424,625 shares during the period. American Century Companies Inc. boosted its stake in shares of IDEAYA Biosciences by 862.7% in the second quarter. American Century Companies Inc. now owns 114,644 shares of the company’s stock valued at $2,410,000 after buying an additional 102,736 shares during the period. Finally, Norges Bank acquired a new stake in IDEAYA Biosciences during the second quarter worth approximately $643,000. Institutional investors and hedge funds own 98.29% of the company’s stock.

Analysts Set New Price Targets

IDYA has been the topic of a number of recent research reports. Truist Financial lowered their price objective on IDEAYA Biosciences from $63.00 to $59.00 and set a “buy” rating on the stock in a research note on Wednesday, August 5th. Royal Bank Of Canada cut their target price on IDEAYA Biosciences from $53.00 to $48.00 and set an “outperform” rating for the company in a research report on Tuesday, July 7th. Wedbush increased their target price on IDEAYA Biosciences from $58.00 to $60.00 and gave the stock an “outperform” rating in a report on Wednesday, August 5th. Citigroup restated a “market outperform” rating on shares of IDEAYA Biosciences in a research report on Tuesday, June 2nd. Finally, Mizuho dropped their price target on IDEAYA Biosciences from $52.00 to $50.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Fourteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $50.12.

IDEAYA Biosciences Trading Up 6.1%

NASDAQ IDYA opened at $42.48 on Wednesday. The firm has a market capitalization of $3.73 billion, a price-to-earnings ratio of -21.90 and a beta of -0.10. The firm’s 50 day simple moving average is $36.57 and its 200 day simple moving average is $32.98. IDEAYA Biosciences, Inc. has a 1 year low of $23.23 and a 1 year high of $42.68.

IDEAYA Biosciences (NASDAQ:IDYA) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($1.22) EPS for the quarter, missing the consensus estimate of ($1.06) by ($0.16). IDEAYA Biosciences had a negative net margin of 75.93% and a negative return on equity of 16.73%. The firm had revenue of $8.86 million for the quarter, compared to analyst estimates of $8.02 million. During the same quarter in the prior year, the firm earned ($0.88) earnings per share. The firm’s revenue for the quarter was up 8800.0% on a year-over-year basis. On average, equities research analysts forecast that IDEAYA Biosciences, Inc. will post -4.38 earnings per share for the current year.

Insider Buying and Selling at IDEAYA Biosciences

In other news, CAO Briseno Andres Ruiz sold 9,550 shares of IDEAYA Biosciences stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $40.01, for a total value of $382,095.50. Following the transaction, the chief accounting officer owned 26,466 shares in the company, valued at approximately $1,058,904.66. This trade represents a 26.52% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 4.70% of the company’s stock.

IDEAYA Biosciences Profile

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.